G
Gilgamesh Pharmaceuticals
Provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders
About Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a clinical-stage biotech startup that operates in the mental health treatment market. The company's primary focus is to revolutionize the treatment of mental illnesses by shifting from symptom management to creating rapid-acting and durable therapies that target the root causes of the diseases.
The company's business model is centered around designing new chemical entities (NCEs), which are essentially new drugs that have not been approved by the FDA yet. These NCEs are created to act through proven mechanisms and are optimized for safety, efficacy, and patient accessibility. This means that Gilgamesh is committed to creating drugs that are not only effective and safe but also easily accessible to patients.
Gilgamesh collaborates with leading research institutions in the biotech field, leveraging their expertise and resources to drive innovation. This collaborative approach allows the company to stay at the forefront of biotech innovation, which is crucial in the highly competitive and rapidly evolving biotech industry.
The company generates revenue through the development and commercialization of its NCEs. Once an NCE is approved by the FDA, Gilgamesh can sell the drug to healthcare providers and patients. The company may also generate income through partnerships with other biotech companies or research institutions.
In summary, Gilgamesh Pharmaceuticals is a clinical-stage biotech company that aims to revolutionize mental health treatment by developing new, safe, and accessible drugs that target the root causes of mental illnesses.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A12 investors entered at this stage
Prime Movers Lab- PIPalo Alto Investors
- GVGron Ventures
Route 66 Ventures
Noetic Fund
JLS Fund
Ayuh Ventures
Alumni Ventures
Negev Capital
Satori Capital
Palo Santo Venture Fund- SNSatori Neuro
Series B and later6 investors entered at this stage
Alumni Ventures- SCSatori Capital
- CUColumbia University
- NCNegev Capital
- AVAyuh Ventures
- PFPalo Santo Venture Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gilgamesh Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gilgamesh Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

